Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas, Inc. (Nasdaq: ARVN) has announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 3, 2020, at 8:30 AM ET. This change is due to the COVID-19 pandemic and related restrictions. Stockholders as of April 6, 2020, are eligible to participate and vote. Registration is required by May 31, 2020, through the Annual Meeting Website. The company encourages all stockholders to vote in advance. Arvinas is focused on developing therapies that degrade disease-causing proteins, with clinical-stage programs targeting prostate and breast cancer.
Arvinas, Inc. (Nasdaq: ARVN) has announced updated safety and efficacy data for ARV-110, a PROTAC protein degrader, during the upcoming 2020 ASCO Annual Meeting. The Phase 1/2 trial targets men with metastatic castration-resistant prostate cancer, showing promising results, including ongoing PSA responses in two patients. The trial has successfully enrolled patients heavily pre-treated with standard therapies such as enzalutamide and abiraterone. Data highlights a sustained safety profile supporting further dose escalation, marking a significant milestone for Arvinas' innovative therapeutic approach.